As of 11:05am ET
| +0.03 / +4.35%|
The 1 analysts offering 12-month price forecasts for Arch Therapeutics Inc have a median target of 1.60, with a high estimate of 1.60 and a low estimate of 1.60. The median estimate represents a +122.22% increase from the last price of 0.72.
The current consensus among 1 polled investment analysts is to Outperform stock in Arch Therapeutics Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.